In view of the uncertain clinical and economic aspects, these guidelines should be implemented while studies are carried out specifically to verify the prevalence of undiagnosed diabetes, to assess the feasibility of the recommended programmes and to provide a short-term assessment of these programmes, including an assessment of follow-up after screening.